Jazz Expands Patent Fight With Avadel Over Narcolepsy Drug Xyrem

Jazz said Avadel’s proposed once-nightly narcolepsy drug, called FT-218, infringes a patent related to Jazz’s twice-nightly Xyrem.

• Jazz is seeking court order blocking Avadel’s drug while lawsuit proceeds and until patent has expired, and cash compensation if claimed formulations or product are made or sold before then, according to complaint filed Wednesday in federal court in Wilmington, Delaware
• Patent was issued Oct. 19 and is titled, “GHB formulation and method for its manufacture”
• Jazz in May sued Avadel over five patents related to Xyrem’s active ingredient and in August sued over a newly issued Xyrem patent; those cases, also ...